Role of nitric oxide in additive anticonvulsant effects of agmatine and morphine

Physiology and Behavior

Volumn 118, Issue , 2013, Pages 52-57

  Payandemehr, Borna ^a,b   Rahimian, Reza ^a,c   Bahremand, Arash ^a   Ebrahimi, Ali ^a,b   Saadat, Seyedehpariya ^a   Moghaddas, Peiman ^a   Fadakar, Kaveh ^a   Derakhshanian, Hoda ^b   Dehpour, Ahmad Reza ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Agmatine; Mice; Morphine; Nitric oxide; Seizure

Indexed keywords

7 NI; AGMATINE; ARGININE; MORPHINE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CLONIC SEIZURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEIZURE THRESHOLD;

EID: 84878552388     PISSN: 00319384     EISSN: 1873507X     Source Type: Journal    
DOI: 10.1016/j.physbeh.2013.05.022     Document Type: Article

References (65)

1. Li G., Regunathan S., Barrow C.J., Eshraghi J., Cooper R., Reis D.J. Agmatine: an endogenous clonidine-displacing substance in the brain. Science 1994, 263:966-969.
2. Piletz J.E., Chikkala D.N., Ernsberger P. Comparison of the properties of agmatine and endogenous clonidine-displacing substance at imidazoline and alpha-2 adrenergic receptors. J Pharmacol Exp Ther 1995, 272:581-587.
3. Regunathan S., Reis D. Characterization of arginine decarboxylase in rat brain and liver. J Neurochem 2000, 74:2201-2208.
4. Yang X.C., Reis D.J. Agmatine selectively blocks the N-methyl-d-aspartate subclass of glutamate receptor channels in rat hippocampal neurons. J Pharmacol Exp Ther 1999, 288:544-549.
5. Raasch W., Schäfer U., Chun J., Dominiak P. Biological significance of agmatine, an endogenous ligand at imidazoline binding sites. Br J Pharmacol 2001, 133:755-780.
6. Kolesnikov Y., Jain S., Pasternak G.W. Modulation of opioid analgesia by agmatine. Eur J Pharmacol 1996, 296:17-22.
7. Aricioglu-Kartal F., Uzbay I.T. Inhibitory effect of agmatine on naloxone-precipitated abstinence syndrome in morphine dependent rats. Life Sci 1997, 61:1775-1781.
8. Aricioglu F., Kan B., Yillar O., Korcegez E., Berkman K. Effect of agmatine on electrically and chemically induced seizures in mice. Ann N Y Acad Sci 2003, 1009:141-146.
9. Demehri S., Homayoun H., Honar H., Riazi K., Vafaie K., Roushanzamir F., et al. Agmatine exerts anticonvulsant effect in mice: modulation by alpha 2-adrenoceptors and nitric oxide. Neuropharmacology 2003, 45:534-542.
10. Bence A.K., Worthen D.R., Stables J.P., Crooks P.A. An in vivo evaluation of the antiseizure activity and acute neurotoxicity of agmatine. Pharmacol Biochem Behav 2003, 74:771-775.
11. Su R.B., Wei X.L., Zheng J.Q., Liu Y., Lu X.Q., Li J. Anticonvulsive effect of agmatine in mice. Pharmacol Biochem Behav 2004, 77:345-349.
12. Homayoun H., Khavandgar S., Dehpour A.R. The involvement of endogenous opioids and nitricoxidergic pathway in the anticonvulsant effects of foot-shock stress in mice. Epilepsy Res 2002, 49:131-142.
13. Riazi K., Honar H., Homayoun H., Rashidi N., Kiani S., Ebrahimkhani M.R., et al. The synergistic anticonvulsant effect of agmatine and morphine: possible role of alpha 2-adrenoceptors. Epilepsy Res 2005, 65:33-40.
14. Homayoun H., Khavandgar S., Namiranian K., Gaskari S.A., Dehpour A.R. The role of nitric oxide in anticonvulsant and proconvulsant effects of morphine in mice. Epilepsy Res 2002, 48:33-41.
15. Sánchez Blázquez P., Boronat M.A., Olmos G., García Sevilla J.A., Garzón J. Activation of I2 imidazoline receptors enhances supraspinal morphine analgesia in mice: a model to detect agonist and antagonist activities at these receptors. Br J Pharmacol 2000, 130:146-152.
16. Roerig S.C. Spinal and supraspinal agmatine activate different receptors to enhance spinal morphine antinociception. Ann N Y Acad Sci 2003, 1009:116-126.
17. Khoshnoodi M.A., Motiei-Langroudi R., Tahsili-Fahadan P., Yahyavi-Firouz-Abadi N., Ghahremani M.H., Dehpour A.R. Involvement of nitric oxide system in enhancement of morphine-induced conditioned place preference by agmatine in male mice. Neurosci Lett 2006, 399:234-239.
18. Demady D.R., Jianmongkol S., Vuletich J.L., Bender A.T., Osawa Y. Agmatine enhances the NADPH oxidase activity of neuronal NO synthase and leads to oxidative inactivation of the enzyme. Mol Pharmacol 2001, 59:24-29.
19. Llorente J., Ulibarri I., Pineda J., Ugedo L. Agmatine morphine interaction on nociception in mice. Ann N Y Acad Sci 2003, 1009:133-136.
20. Feng Y. Agmatine suppresses nitric oxide production and attenuates hypoxic-ischemic brain injury in neonatal rats. Pediatr Res 2002, 52:606-611.
21. Bahremand A., Payandemehr B., Rahimian R., Ziai P., Pourmand N., Loloee S., et al. The role of 5-HT3 receptors in the additive anticonvulsant effects of citalopram and morphine on pentylenetetrazole-induced clonic seizures in mice. Epilepsy Behav 2011, 21:122-127.
22. Bahremand A., Ziai P., Khodadad T.K., Payandemehr B., Rahimian R., Ghasemi A., et al. Agmatine enhances the anticonvulsant effect of lithium chloride on pentylenetetrazole-induced seizures in mice: involvement of l-arginine/nitric oxide pathway. Epilepsy Behav 2010, 18:186-192.
23. Löscher W. Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and post-status epilepticus models of temporal lobe epilepsy. Epilepsy Res 2002, 50:105-123.
24. Bahremand A., Ziai P., Payandemehr B., Rahimian R., Amouzegar A., Khezrian M., et al. Additive anticonvulsant effects of agmatine and lithium chloride on pentylenetetrazole-induced clonic seizure in mice: Involvement of [alpha] 2-adrenoceptor. Eur J Pharmacol 2011, 666:93-99.
25. Swinyard E.A., Kupferberg H.J. Antiepileptic drugs: detection, quantification, and evaluation. Fed Proc 1985, 44:2629-2633.
26. Loscher W., Honack D., Fassbender C.P., Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazole seizure models. Epilepsy Res 1991, 8:171-189.
27. Kaputlu I., Uzbay T. L-NAME inhibits pentylenetetrazole and strychnine-induced seizures in mice. Brain Res 1997, 753:98-101.
28. Montaser-Kouhsari L., Payandemehr B., Gholipour T., Ziai P., Nabavizadeh P., Ghasemi A., et al. A role for opioid system in the proconvulsant effects of sildenafil on the pentylenetetrazole-induced clonic seizure in mice. Seizure 2011, 20:409-413.
29. Lauretti G.R., Ahmad I., Pleuvry B.J. The activity of opioid analgesics in seizure models utilizing N-methyl-dl-aspartic acid, kainic acid, bicuculline and pentylenetetrazole. Neuropharmacology 1994, 33:155-160.
30. Shafaroodi H., Asadi S., Sadeghipour H., Ghasemi M., Ebrahimi F., Tavakoli S., et al. Role of ATP-sensitive potassium channels in the biphasic effects of morphine on pentylenetetrazole-induced seizure threshold in mice. Epilepsy Res 2007, 75:63-69.
31. Foote F., Gale K. Proconvulsant effect of morphine on seizures induced by pentylenetetrazol in the rat. Eur J Pharmacol 1984, 105:179-184.
32. Khavandgar S., Homayoun H., Dehpour A.R. Mediation of nitric oxide in inhibitory effect of morphine against electroshock-induced convulsions in mice. Pharmacol Biochem Behav 2003, 74:795-801.
33. Wikler A., Altschul S. Effects of methadone and morphine on the electroencephalogram of the dog. J Pharmacol Exp Ther 1950, 98:437-446.
34. Reis D.J., Regunathan S. Is agmatine a novel neurotransmitter in brain?. Trends Pharmacol Sci 2000, 21:187-193.
35. Halaris A., Piletz J.E. Relevance of imidazoline receptors and agmatine to psychiatry: a decade of progress. Ann N Y Acad Sci 2003, 1009:1-20.
36. Molderings G.J., Haenisch B. Agmatine (decarboxylated l-arginine): physiological role and therapeutic potential. Pharmacol Ther 2011, 133(3):351-365.
37. Yesilyurt O., Uzbay I.T. Agmatine potentiates the analgesic effect of morphine by an alpha(2)-adrenoceptor-mediated mechanism in mice. Neuropsychopharmacology 2001, 25:98-103.
38. Tahsili-Fahadan P., Yahyavi-Firouz-Abadi N., Khoshnoodi M.A., Motiei-Langroudi R., Tahaei S.A., Ghahremani M.H., et al. Agmatine potentiates morphine-induced conditioned place preference in mice: modulation by alpha2-adrenoceptors. Neuropsychopharmacology 2006, 31:1722-1732.
39. Li J., Li X., Pei G., Qin B.Y. Correlation between inhibitions of morphine withdrawal and nitric-oxide synthase by agmatine. Zhongguo Yao Li Xue Bao 1999, 20:375-380.
40. Aricioglu F., Means A., Regunathan S. Effect of agmatine on the development of morphine dependence in rats: potential role of cAMP system. Eur J Pharmacol 2004, 504:191-197.
41. Galea E., Regunathan S., Eliopoulos V., Feinstein D.L., Reis D.J. Inhibition of mammalian nitric oxide synthases by agmatine, an endogenous polyamine formed by decarboxylation of arginine. Biochem J 1996, 316(Pt 1):247-249.
42. Ruiz-Durantez E., Ruiz-Ortega J.A., Pineda J., Ugedo L. Effect of agmatine on locus coeruleus neuron activity: possible involvement of nitric oxide. Br J Pharmacol 2002, 135:1152-1158.
43. Brignola G., Calignano A., Di Rosa M. Modulation of morphine antinociception in the mouse by endogenous nitric oxide. Br J Pharmacol 1994, 113:1372-1376.
44. Luszczki J.J., Czernecki R., Wojtal K., Borowicz K.K., Czuczwar S.J. Agmatine enhances the anticonvulsant action of phenobarbital and valproate in the mouse maximal electroshock seizure model. J Neural Transm 2008, 115:1485-1494.
45. Goracke-Postle C.J., Overland A.C., Stone L.S., Fairbanks C.A. Agmatine transport into spinal nerve terminals is modulated by polyamine analogs. J Neurochem 2007, 100:132-141.
46. Tadano T. Behavioral pharmacology of alkali metals. (3). Changes in polyamine levels in the brain and emotional behavior of aggressive mice originally isolated and returned to a group situation. Nippon Yakurigaku Zasshi 1974, 70:457-464.
47. Genedani S., Bernardi M., Tagliavini S., Bertolini A. ODC-polyamine system is involved in morphine analgesia. Life Sci 1989, 44:525-531.
48. Gilad G.M., Gilad V.H. Brain polyamine stress response: recurrence after repetitive stressor and inhibition by lithium. J Neurochem 1996, 67:1992-1996.
49. Lewis B., Wellmann K.A., Barron S. Agmatine reduces balance deficits in a rat model of third trimester binge-like ethanol exposure. Pharmacol Biochem Behav 2007, 88:114-121.
50. Laschet J., Trottier S., Leviel V., Guibert B., Bansard J.Y., Chauvel P., et al. Heterogeneous distribution of polyamines in temporal lobe epilepsy. Epilepsy Res 1999, 35:161-172.
51. Hayashi Y., Hattori Y., Moriwaki A., Lu Y.F., Hori Y. Increases in brain polyamine concentrations in chemical kindling and single convulsion induced by pentylenetetrazol in rats. Neurosci Lett 1993, 149:63-66.
52. Snyder S.H., Bredt D.S. Biological roles of nitric oxide. Sci Am 1992, 266:68-71.
53. Bagetta G., Paoletti A.M., Leta A., Del Duca C., Nistico R., Rotiroti D., et al. Abnormal expression of neuronal nitric oxide synthase triggers limbic seizures and hippocampal damage in rat. Biochem Biophys Res Commun 2002, 291:255-260.
54. Kivastik T., Rutkauskaite J., Zharkovsky A. Nitric oxide synthesis inhibition attenuates morphine-induced place preference. Pharmacol Biochem Behav 1996, 53:1013-1015.
55. Adams M.L., Kalicki J.M., Meyer E.R., Cicero T.J. Inhibition of the morphine withdrawal syndrome by a nitric oxide synthase inhibitor, NG-nitro-l-arginine methyl ester. Life Sci 1993, 52:245-249.
56. Sardo P., D'Agostino S., Rizzo V., Carletti F., Lonobile G., Ferraro G. In the rat maximal dentate activation model of partial complex epilepsy, the anticonvulsant activity of levetiracetam is modulated by nitric oxide-active drugs. J Neural Transm 2009, 116:831-839.
57. Talarek S., Fidecka S. Role of nitric oxide in anticonvulsant effects of benzodiazepines in mice. Pol J Pharmacol 2003, 55:181-191.
58. Theard M.A., Baughman V.L., Wang Q., Pelligrino D.A., Albrecht R.F. The role of nitric oxide in modulating brain activity and blood flow during seizure. Neuroreport 1995, 6:921-924.
59. Osonoe K., Mori N., Suzuki K., Osonoe M. Antiepileptic effects of inhibitors of nitric oxide synthase examined in pentylenetetrazol-induced seizures in rats. Brain Res 1994, 663:338-340.
60. 3 receptor mediates the dose-dependent effects of citalopram on pentylenetetrazole-induced clonic seizure in mice: Involvement of nitric oxide. Epilepsy Res 2012, 101:217-227.
61. Uzum G., Akgun-Dar K., Bahcekapili N., Diler A.S., Ziylan Y.Z. Nitric oxide involvement in seizures elicited by pentylentetrazol and sex dependence. Int J Neurosci 2005, 115:1503-1514.
62. Alexander C.B., Ellmore T.M., Kokate T.G., Kirkby R.D. Further studies on anti- and proconvulsant effects of inhibitors of nitric oxide synthase in rodents. Eur J Pharmacol 1998, 344:15-25.
63. Garthwaite J. Glutamate, nitric oxide and cell-cell signalling in the nervous system. Trends Neurosci 1991, 14:60-67.
64. Manzoni O., Prezeau L., Marin P., Deshager S., Bockaert J., Fagni L. Nitric oxide-induced blockade of NMDA receptors. Neuron 1992, 8:653-662.
65. Gao Y., Gumusel B., Koves G., Prasad A., Hao Q., Hyman A., et al. Agmatine: a novel endogenous vasodilator substance. Life Sci 1995, 57:83-86.